

Topical Recommended Reading List : January 2012
Lectures recommandées sur un sujet particulier : janvier 2012

Alzheimer disease awareness month: January 2012: focus on prevention

Diagnostic guidelines

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC et al. **The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.** Alzheimers Dement 2011;7(3):270-279. [link to abstract](#)
2. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P et al. **Revising the definition of Alzheimer's disease: a new lexicon.** Lancet Neurol. 2010;9(11):1118-1127. [link to abstract](#)
3. Jessen F, Wiese B, Bickel H, Eiffländer-Gorfer S, Fuchs A, Kaduszkiewicz H et al. **Prediction of dementia in primary care patients.** PLoS One 2011;6(2):e16852. [link to abstract](#)
4. Lopez OL, McDade E, Riverol M, Becker JT. **Evolution of the diagnostic criteria for degenerative and cognitive disorders.** Curr Opin Neurol 2011;24(6):532-541. [link to abstract](#)
5. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH et al. **The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.** Alzheimers Dement 2011;7(3):263-269. [link to abstract](#)
6. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagin AM et al. **Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.** Alzheimers Dement 2011;7(3):280-292. [link to abstract](#)

Pathophysiology

7. Abeti R, Abramov AY, Duchen MR. **Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death.** Brain 2011;134(Pt 6):1658-1672. [link to abstract](#)
8. Abramov AY, Ionov M, Pavlov E, Duchen MR. **Membrane cholesterol content plays a key role in the neurotoxicity of β-amyloid: implications for Alzheimer's disease.** Aging Cell 2011;10(4):595-603. [link to abstract](#)
9. Camicioli R, Sabino J, Gee M, Bouchard T, Fisher N, Hanstock C et al. **Ventricular dilatation and brain atrophy in patients with Parkinson's disease with incipient dementia.** Mov Disord 2011;26(8):1443-1450. [link to abstract](#)
10. Cordonnier C, van der Flier WM. **Brain microbleeds and Alzheimer's disease: innocent observation or key player?** Brain 2011;134(Pt 2):335-344. [link to abstract](#)

11. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C et al. **Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association.** Stroke 2011;42(9):2672-2713. [link to abstract](#)
12. Maruszak A, Zekanowski C. **Mitochondrial dysfunction and Alzheimer's disease.** Prog Neuropsychopharmacol Biol Psychiatry 2011;35(2):320-330. [link to abstract](#)
13. Mogi M, Horiuchi M. **Clinical Interaction between Brain and Kidney in Small Vessel Disease.** Cardiol Res Pract 2011; [link to abstract](#) open access [link to full text](#)
14. Panza F, Solfrizzi V, Frisardi V, Maggi S, Sancarlo D, Adante F et al. **Different models of frailty in predementia and dementia syndromes.** J Nutr Health Aging 2011;15(8):711-719. [link to abstract](#)
15. Strachan MW. R D Lawrence Lecture 2010. **The brain as a target organ in Type 2 diabetes: exploring the links with cognitive impairment and dementia.** Diabet Med 2011;28(2):141-147. [link to abstract](#)

Risk factors and prevention

16. Anstey KJ, Cherbuin N, Budge M, Yong J. **Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies.** Obes Rev 2011;12(5):e426-e437. [link to abstract](#)
17. Alvarez-Sabin J, Román GC. **Citicoline in vascular cognitive impairment and vascular dementia after stroke.** Stroke 2011;42(1 Suppl):S40-S43. free full text available [link to abstract](#)
18. Arntzen KA, Schirmer H, Wilsgaard T, Mathiesen EB. **Impact of cardiovascular risk factors on cognitive function: the Tromsø study.** Eur J Neurol 2011;18(5):737-743. [link to abstract](#)
19. Barnes DE, Yaffe K. **The projected effect of risk factor reduction on Alzheimer's disease prevalence.** Lancet Neurol 2011;10(9):819-828. [link to abstract](#)
20. Béjot Y, Aboa-Eboulé D, Durier J, Rouaud O, Jacquin A, Ponavoy E et al. **Prevalence of early dementia after first-ever stroke: a 24-year population-based study.** Stroke 2011;42(3):607-612. [link to abstract](#)
21. Bilbul M, Schipper HM. **Risk profiles of Alzheimer disease.** Can J Neurol Sci 2011;38(4):580-592. [link to abstract](#)
22. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH et al. **Extended results of the Alzheimer's disease anti-inflammatory prevention trial.** Alzheimers Dement 2011;7(4):402-411. [link to abstract](#)
23. Craggs L, Kalaria RN. **Revisiting dietary antioxidants, neurodegeneration and dementia.** Neuroreport 2011;22(1):1-3. [link to abstract](#)
24. Daviglus ML, Plassman BL, Pirzada A, Bell CC, Bowen PE, Burke JR et al. **Risk factors and preventive interventions for Alzheimer disease:** state of the science. Arch Neurol 2011;68(9):1185-1190. [link to abstract](#)
25. Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES Jr, Cox NJ et al. **National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline.** Ann Intern Med 2010;153(3):176-181. [link to abstract](#)
26. Dickens AP, Lang JA, Langa KM, Kos K, Llewellyn DJ. **Vitamin D, cognitive dysfunction and dementia in older adults.** CNS Drugs 2011;25(8):629-639. [link to abstract](#)

27. Diener HC. **Prevention of dementia should start 20 years before symptoms become apparent.** Eur Heart J 2011;32(18):2228-2230. [link to abstract](#)
28. Fratiglioni L, Qiu C. **Prevention of cognitive decline in ageing: dementia as the target, delayed onset as the goal.** Lancet Neurol 2011;10(9):778-779. no abstract
29. Frisardi V, Panza F, Seripa D, Imbimbo BP, Vendemiale G, Pilotto A et al. **Nutraceutical properties of Mediterranean diet and cognitive decline: possible underlying mechanisms.** J Alzheimers Dis 2010;22(3):715-740. [link to abstract](#)
30. Ho RC, Cheung MW, Fu E, Win HH, Zaw MH, Ng A et al. **Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression.** Am J Geriatr Psychiatry 2011;19(7):607-617. [link to abstract](#)
31. Ho YS, SoKF, Chang RC. **Drug discovery from Chinese medicine against neurodegeneration in Alzheimer's and vascular dementia.** Chin Med 2011;6:15-20. [link to abstract](#)
32. Howes MJ, Perry E. **The role of phytochemicals in the treatment and prevention of dementia.** Drugs Aging 2011;28(6):439-468. [link to abstract](#)
33. Ionov M, Burchell V, Klajnert B, Bryszewska M, Abramov AY. **Mechanism of neuroprotection of melatonin against beta-amyloid neurotoxicity.** Neuroscience 2011;180:229-237. [link to abstract](#)
34. Kesse-Guyot E, Fezeu L, Jeandel C, Ferry M, Andreeva V, Amieva H et al. **French adults' cognitive performance after daily supplementation with antioxidant vitamins and minerals at nutritional doses: a post hoc analysis of the Supplementation in Vitamins and Mineral Antioxidants (SU.VI.MAX) trial.** Am J Clin Nutr 2011;94(3):892-899. [link to abstract](#)
35. Leoutsakos JM, Muthén BO, Breitner JC, Lyketsos CG; For the ADAPT Research Team. **Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial.** Int J Geriatr Psychiatry 2011; epub ahead of print. [link to abstract](#)
36. Li J, Wang YJ, Zhang M, XuZQ, Gao CY, Fang CQ et al. **Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease.** Neurology 2011;76(17):1485-1491. [link to abstract](#)
37. Lin FR, Metter EJ, O'Brien RJ, Resnick SM, Zonderman AB, Ferrucci L **Hearing loss and incident dementia.** Arch Neurol 2011;68(2):214-220. [link to abstract](#)
38. Luoma PV. **Gene-activation mechanisms in the regression of atherosclerosis, elimination of diabetes type 2, and prevention of dementia.** Curr Mol Med 2011;11(5):391-400. [link to abstract](#)
39. Mishra S, Mishra M, Seth P, Sharma SK. **Tetrahydrocurcumin confers protection against amyloid β-induced toxicity.** Neuroreport 2011;22(1):23-27. [link to abstract](#)
40. Naftolin F, Harman SM. **Preventing Alzheimer disease and cognitive decline.** Ann Intern Med 2011;154(3):211-212. no abstract
41. Nakagawa K, Kiko T, Miyazawa T, Carpentero Burdeos G, Kimura F, Satoh A, Miyazawa T. **Antioxidant effect of astaxanthin on phospholipid peroxidation in human erythrocytes.** Br J Nutr 2011;105(11):1563-1571. [link to abstract](#)
42. Nie Q, Du XG, Geng MY. **Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.** Acta Pharmacol Sin 2011;32(5):545-551. [Link to abstract](#)

43. O'Brien JT, Burns A; BAP Dementia Consensus Group. **Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.** J Psychopharmacol 2011;25(8):997-1019. [link to abstract](#)
44. Panza F, Frisardi V, Seripa D, Imbimbo BP, Sancarlo D, D'Onofrio G et al. **Metabolic syndrome, mild cognitive impairment, and dementia.** Curr Alzheimer Res 2011;8(5):492-509. [link to abstract](#)
45. Perissinotto CM, Valcour V. **Preventing dementia: is there hope for progress?** Am Fam Physician 2011;83(9):1034-1035. No abstract
46. Perry E, Howes MJ. **Medicinal plants and dementia therapy: herbal hopes for brain aging?** CNS Neurosci Ther 2011;17(6):683-698. [link to abstract](#)
47. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N et al. **Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.** J Alzheimers Dis 2011;26(Supple 3):321-329. [link to abstract](#)
48. Roher AE, Tyas SL, Maarouf CL, Daugs ID, Kokjohn TA, Emmerling MR et al. **Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia.** Alzheimers Dement 2011;7(4):436-444. [link to abstract](#)
49. Sachdev PS. **Alzheimer disease: homocysteine and alzheimer disease: an intervention study.** Nat Rev Neurol 2011;7(1):9-10. No abstract
50. Savica R, Petersen RC. **Prevention of dementia.** Psychiatr Clin North Am 2011;34(1):127-145. [link to abstract](#)
51. Schipper HM. **Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment.** Neurobiol Aging 2011;32(5):778-790. [link to abstract](#)
52. Schipper HM, Liberman A, Kelner N, Babins L, Fried L, Bilbul M. **ARAC--The Montreal Jewish General Hospital Alzheimer Risk Assessment Clinic.** Can J Neurol Sci 2011;38(4):600-611. [link to abstract](#)
53. Schipper HM. **Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention.** Alzheimers Dement 2011;7(4):e118-e123. [link to abstract](#)
54. Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino G, Imbimbo BP et al. **Diet and Alzheimer's disease risk factors or prevention: the current evidence.** Expert Rev Neurother 2011;11(5):677-708. [link to abstract](#)
55. Solfrizzi V, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, D'Onofrio G et al. **Mediterranean diet in predementia and dementia syndromes.** Curr Alzheimer Res 2011;8(5):520-542. [link to abstract](#)
56. Solfrizzi V, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Vendemiale G et al. **Dietary fatty acids in dementia and predementia syndromes: epidemiological evidence and possible underlying mechanisms.** Ageing Res Rev 2010;9(2):184-199. [link to abstract](#)
57. Staessen JA, Thijs L, Richart T, Odili AN, Birkenhäger WH. **Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia.** Hypertension 2011;57(2):e6-e7. no abstract
58. Sureda FX, Junyent F, Verdaguer E, Auladell C, Pelegri C, Vilaplana J et al. **Antia apoptotic drugs: a therapeutic strategy for the prevention of neurodegenerative diseases.** Curr Pharm Des 2011;17(3):230-245. [link to abstract](#)
59. Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B et al. **Prevention trials in Alzheimer's disease: an EU-US task force report.** Prog Neurobiol 2011;95(4):594-600. [link to abstract](#)

60. Wehling M, Groth H. **Challenges of longevity in developed countries: vascular prevention of dementia as an immediate clue to tackle an upcoming medical, social and economic stretch.** Neurodegener Dis 2011;8(5):275-282. [link to abstract](#)
61. Woo HN, Baik SH, Park JS, Gwon AR, Yang S, Yun YK et al. **Secretases as therapeutic targets for Alzheimer's disease.** Biochem Biophys Res Commun 2011;404(1):10-15. [link to abstract](#)
62. Yuan JP, Peng J, Yin K, Wang JH. **Potential health-promoting effects of astaxanthin: a high-value carotenoid mostly from microalgae.** Mol Nutr Food Res 2011;55(1):150-165. [link to abstract](#)

Emerging themes

63. Brodaty H, Breteler MM, Dekisky ST, Dorenlot P, Fratiglioni L, Hock C et al. **The world of dementia beyond 2020.** J Am Geriatr Soc 2011;59(5):923-927. [link to abstract](#)
64. Dursun E, Gezen-Ak D, Yilmazer S. **A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid- β and preventing the amyloid- β induced alterations by vitamin D in cortical neurons.** J Alzheimers Dis 2011;23(2):207-219. [link to abstract](#)
65. Filley CM, Anderson CA. **Dementia: five new things.** Neurology 2011;76(7 Suppl 2):S26-S30 no abstract [link to full text article](#)
66. Godle TE, Schneider LS, Koo EH. **Anti- $\alpha\beta$ therapeutics in Alzheimer's disease: the need for a paradigm shift.** Neuron 2011;69(2):203-213. [link to abstract](#)
67. Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frölich L et al. **The future of Alzheimer's disease: the next 10 years.** Prog Neurobiol 2011;95(4):718-728. [link to abstract](#)
68. Kuller LH, Lopez OL. **Dementia and Alzheimer's disease: a new direction. the 2010 Jay L. Foster Memorial lecture.** Alzheimers Dement 2011;7(5):540-550. [link to abstract](#)
69. Price AE, Corwin SJ, Friedman DB, Laditka SB, Colabianchi N, Montgomery KM et al. **Older adults' perceptions of physical activity and cognitive health: implications for health communication.** Health Educ Behav 2011;38(1):15-24. [link to abstract](#)
70. Sacco RL. **Achieving ideal cardiovascular and brain health: opportunity amid crisis: (AHA) Presidential Address at the American Heart Association 2010 Scientific Sessions.** Circulation 2011;123(22):2653-2657. [link to abstract](#)

To receive a copy of any article(s), please contact the / Pour recevoir une copie d'article contactez le

[SHRTN Library Service / Service bibliothèque de RTRSPA](#)

When making a request, provide the corresponding number(s) for the articles(s) you would like to receive in full text. Due to copyright policies, we are only able to provide articles via fax or mail. Indiquez le numéro correspondant à l'article que vous désirez recevoir en texte intégral. Veuillez noter que la loi sur les droits d'auteurs nous permet de vous faire parvenir les articles par télécopieur ou par courrier seulement.

SHRTN is funded in part by the Ontario Ministry of Health and Long Term Care in conjunction with its partners listed here.

RTRSPA est financé en partie par le Ministère de la santé et des soins de longue durée de l'Ontario conjointement avec ces partenaires suivants énumérés ici.